BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study

被引：0
作者：
Roeker, Lindsey E. [1 ]
Han, Yi [2 ]
Teschemaker, Anna [3 ]
Mato, Anthony R. [1 ]
Thompson, Meghan C. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
[2] Vinzent Strategies, Blue Bell, PA USA
[3] AstraZeneca, Gaithersburg, MD USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2025年 / 100卷 / 04期
关键词：
Bruton tyrosine kinase inhibitor; chronic lymphocytic leukemia; real-world evidence; small lymphocytic lymphoma; venetoclax;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：720 / 723
页数：4
相关论文
共 6 条
  • [1] Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia
    Davids, Matthew S.
    Telford, Claire
    Abhyankar, Sarang
    Waweru, Catherine
    Ringshausen, Ingo
    [J]. LEUKEMIA & LYMPHOMA, 2021, 62 (10) : 2342 - 2351
  • [2] ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia
    Eichhorst, B.
    Ghia, P.
    Niemann, C. U.
    Kater, A. P.
    Gregor, M.
    Hallek, M.
    Jerkeman, M.
    Buske, C.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (09) : 762 - 768
  • [3] Long-term progression-free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons
    Messori, Andrea
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (01) : 60 - 66
  • [4] Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Munir, Talha
    Brown, Jennifer R.
    O'Brien, Susan
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Reddy, Nishitha M.
    Coutre, Steven
    Tam, Constantine S.
    Mulligan, Stephen P.
    Jaeger, Ulrich
    Kipps, Thomas J.
    Moreno, Carol
    Montillo, Marco
    Burger, Jan A.
    Byrd, John C.
    Hillmen, Peter
    Dai, Sandra
    Szoke, Anita
    Dean, James P.
    Woyach, Jennifer A.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) : 1353 - 1363
  • [5] Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Seymour, J. F.
    Kipps, T. J.
    Eichhorst, B.
    Hillmen, P.
    D'Rozario, J.
    Assouline, S.
    Owen, C.
    Gerecitano, J.
    Robak, T.
    De la Serna, J.
    Jaeger, U.
    Cartron, G.
    Montillo, M.
    Humerickhouse, R.
    Punnoose, E. A.
    Li, Y.
    Boyer, M.
    Humphrey, K.
    Mobasher, M.
    Kater, A. P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) : 1107 - 1120
  • [6] Next-Generation Sequencing-Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Simon, Florian
    Bohn, Jan-Paul
    [J]. CURRENT ONCOLOGY REPORTS, 2023, 25 (10) : 1181 - 1189
1